Core Insights - The onset age of male menopause (LOH) in China has advanced from 45 to 38 years, with 38% of men over 40 experiencing testosterone deficiency, highlighting a growing health crisis among men [1][2] - LAIFE has launched a revolutionary product, LAIFE "乐维源," which utilizes AI-driven precision testosterone maintenance solutions to address this issue [1][3] Company Insights - LAIFE "乐维源" leverages an AI formulation platform, RevOrgan, to avoid traditional supplement pitfalls by implementing a three-step development process: intelligent screening, collaborative formulation, and environmental simulation [3][6] - The proprietary PERFORMAX formula includes scientifically validated ingredients such as Physta and KSM-66, which have shown significant improvements in testosterone levels and overall health metrics [6][7] - The product's innovative approach signifies a shift in male health management from symptom relief to root cause regulation, establishing a new standard in the industry [7] Industry Insights - The technology breakthrough represented by LAIFE "乐维源" redefines the technical boundaries of male anti-aging products, offering more stable testosterone level regulation compared to traditional supplements [7] - The cultural perception of men as "silent bearers" contributes to the avoidance of addressing testosterone deficiency, making LAIFE "乐维源" not just a technological advancement but also a catalyst for changing societal attitudes [7] - The product's entry into multiple markets exemplifies a replicable model for personalized anti-aging solutions, marking a transition into the era of precision medicine in male health management [7]